Saag, Kenneth G <br/><br/>
Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.  [electronic resource] 

 -  Arthritis & rheumatology (Hoboken, N.J.)  07 2019 
 - 1174-1184 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2326-5205 
<br/><br/><label>Standard No.: </label>10.1002/art.40874  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Absorptiometry, Photon<br/>Aged<br/>Bone Density<br/>Bone Density Conservation Agents--therapeutic use<br/>Bone Remodeling<br/>Collagen Type I--metabolism<br/>Denosumab--therapeutic use<br/>Double-Blind Method<br/>Female<br/>Femur Neck--diagnostic imaging<br/>Glucocorticoids--adverse effects<br/>Hip--diagnostic imaging<br/>Humans<br/>Lumbar Vertebrae--diagnostic imaging<br/>Male<br/>Middle Aged<br/>Osteoporosis--chemically induced<br/>Osteoporotic Fractures--prevention & control<br/>Peptide Fragments--metabolism<br/>Peptides--metabolism<br/>Procollagen--metabolism<br/>Risedronic Acid--therapeutic use<br/>Treatment Outcome